Janux Therapeutics (NASDAQ:JANX) Insider Sells $56,947.77 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the transaction, the insider owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Janux Therapeutics Trading Up 1.3%

JANX traded up $0.17 during trading on Thursday, reaching $13.76. 621,032 shares of the company were exchanged, compared to its average volume of 914,938. The stock has a market cap of $839.08 million, a P/E ratio of -7.48 and a beta of 2.53. The firm has a 50 day moving average of $14.51 and a 200 day moving average of $15.58. Janux Therapeutics, Inc. has a 52 week low of $12.12 and a 52 week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.36 million. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on JANX. Wedbush lowered their price objective on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Weiss Ratings upgraded Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Guggenheim reduced their price target on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, May 8th. JonesTrading reduced their price target on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Finally, UBS Group lowered Janux Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.85.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Nano Cap New Millennium Growth Fund L P acquired a new position in Janux Therapeutics during the 4th quarter worth $34,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Janux Therapeutics in the fourth quarter valued at $51,000. Osaic Holdings Inc. lifted its holdings in shares of Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after buying an additional 3,037 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after buying an additional 2,502 shares during the period. Finally, Winthrop Capital Management LLC acquired a new stake in shares of Janux Therapeutics in the third quarter valued at $106,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.